【摘要】 目的探讨尿肝型脂肪酸结合蛋白(L-FABP)与慢性肾脏病进展的关系。方法选取149例慢性肾脏病患者,使用简化的MORD公式估计的肾小球滤过率对其进行CKD分期,以67例健康体检者为对照组,酶联免疫吸附法(ELISA)测定尿L-FABP含量,同时检测尿肌酐、肾功能、肝功能、血红蛋白(Hb)和尿蛋白等指标,并进行统计分析。结果随着慢性肾病病程进展,患者尿L-FABP水平逐渐上升,亚组比较显示,CKD1期组尿L-FABP水平高于健康对照组(P<0.05),CKD2期组尿L-FABP水平高于CKD1期组(P<0.01),CKD3期组尿L-FABP水平高于CKD2期组(P<0.01),CKD4期组尿LFABP水平高于CKD3期组(P<0.01),CKD5期组尿L-FABP水平高于CKD4期组(P<0.01)。尿L-FABP水平与e GFR呈负相关(r=-0.742,P<0.05),尿L-FABP水平与Scr呈正相关(r=0.836,P<0.05)。结论尿L-FABP水平不仅可早期预测慢性肾脏病的发生,还可监测慢性肾脏病的进展。更多还原

【Abstract】 Objective To investigate the correlation of urinary liver-type fatty-acid binding protein with progression of chronic kidney disease. Methods 149 cases chronic kidney disease patients without liver damage were recruited in this study. The patients were divided into five groups based on the estimation of the glomerular filtration rate. Urinary L-FABP was measured by enzyme linked immunosorbent assay( ELISA),while urinary creatinine,renal function, liver function, hemoglobin and urinary protein were measured by respective biochemical or immunological methods. Results With the progression of diabetic chronic kidney disease,Urinary L-FABP gradually increased( P < 0. 01). Subgroup analysis showed that the urine L-FABP of CKD1 group was higher than that of healthy group( P < 0. 05),the urinary L-FABP of CKD2 group was higher than that of group CKD1 group( P < 0. 01),the urinary L-FABP of CKD3 group was higher than that of group CKD2 group( P <0. 01),the urinary L-FABP of CKD4 group was higher than that of group CKD3 group( P < 0. 01),the urinary L-FABP of CKD5 group was higher than that of group CKD4 group( P < 0. 01). The urinary L-FABP was negatively correlated with e GFR( r =- 0. 742,P < 0. 05),and positively correlated with Scr( r = 0. 836,P <0. 05). Conclusion The urinary L-FABP could not only predict the occurrence of early chronic kidney disease,and also monitor the progression of chronic kidney disease.更多还原